Professor Jacob George is Professor of Cardiovascular Medicine & Therapeutics and R&D Director for the East of Scotland. He is one of four members of the NHS Research Scotland Strategy Board. Professor George is Director of the Tayside Medical Sciences Centre (TASC - https://www.ahspartnership.org.uk/tasc ) comprising of the UKCRN registered Tayside Clinical Trials Unit, Clinical Research Centre, Tayside Biorepository, Clinical Research Imaging Facility, Research Governance, TASC Legal, Research Finance, Commercial and Non-Commercial Trial teams as well as the East of Scotland Research Ethics Service. He is actively involved in Medicines Governance in Scotland, being both the Chair of the Medicines Advisory Group since 2009 and Tayside representative on the Scottish Medicines Consortium (SMC) since 2010. He also sits on the National Appeals Panel for drugs not approved by the SMC. He was recently appointed by the Minister of Health, Malaysia as an International Expert Member of the Malaysian Scientific Review Panel for Phase I Clinical Trials.
Professionally, he is a Consultant Physician in qualified in Clinical Pharmacology and General Internal Medicine and is an accredited European Hypertension Specialist. His clinical interest is in managing patients with high Cardiovascular risk. He is also Professor of Cardiovascular Medicine & Therapeutics at the University of Dundee Medical School. His research interests are focused on three main areas: Understanding mechanisms how oxidative stress affects vascular biology and how it can be modified to improve clinical outcomes. He is currently Chief Investigator for the ALLAY (Allopurinol in Resistant Hypertension), ALFIE (Allopurinol in Functional Impairment in the Elderly) and VESUVIUS (effect of e-cigarette versus traditional cigarettes on vascular function) trial. In addition to this he is Principal Investigator for numerous Commercially Sponsored clinical trials. His research publications have been covered by more than 50 news organizations worldwide and he has conducted more than 80 media interviews including live television broadcasts to national and international media on the results of his research.
Lists of his various awards, local, national and international roles, grant funding and publications are contained within his CV (upon request)
'A common missense variant of LILRB5 is associated with statin intolerance and myalgia' European Heart Journal, vol. 38, no. 48, pp. 3569-3575. DOI:
'CKM Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia' Circulation: Cardiovascular Genetics, vol. 10, no. 4, e001737 . DOI:
'Population-Level Incidence and Monitoring of Adverse Drug Reactions with Long-term Amiodarone Therapy' Cardiovascular Therapeutics, vol. 35, no. 3, e12258, pp. 1-7. DOI:
'A descriptive study of hot aches: a previously unreported winter climbing phenomenon' Sports Medicine - Open, vol. 2, 36. DOI:
'Common Creatine Kinase gene mutation results in falsely reassuring CK levels in muscle disorders' QJM : an International Journal of Medicine, vol. 109, no. 6, pp. 413-414. DOI:
'Allopurinol and oxypurinol promote osteoblast differentiation and increase bone formation' Experimental Cell Research, vol. 342, no. 2, pp. 166-174. DOI:
'Association between allopurinol use and hip fracture in older patients' Bone, vol. 84, pp. 189-193. DOI:
'Mean Hb A1c and mortality in diabetic individuals with heart failure: a population cohort study' European Journal of Heart Failure, vol. 18, no. 1, pp. 94-102. DOI:
'High B-type natriuretic peptide hypertensives at target blood pressure potential role of beta-blockers to reduce their elevated risk' Hypertension, vol. 66, no. 5, pp. 927-932. DOI:
'A common missense variant of LILRB5 is associated with statin intolerance: A Go DARTS study' 65th American Society of Human Genetics Annual Meeting, Baltimore, United States, 6/10/15 - 10/10/15, .
'Dose-dependent effects of Allopurinol on human foreskin fibroblast cell and human umbilical vein endothelial cell under hypoxia' PLo S ONE, vol. 10, no. 4, e0123649. DOI:
'Effect of warfarin on survival in patients with concomitant left ventricular systolic dysfunction and pulmonary hypertension: a population cohort study' European Journal of Heart Failure, vol. 17, no. 1, pp. 90-7. DOI:
'Home blood pressure monitoring' European Cardiology Review, vol. 10, no. 2, pp. 95-101. DOI:
'Cardiovascular risk associated with sodium-containing medicines' Expert Opinion on Drug Safety, vol. 13, no. 11, pp. 1515-1523. DOI:
'High BNP levels in rheumatoid arthritis are related to inflammation but not to left ventricular abnormalities: a prospective case-control study' International journal of cardiology, vol. 172, no. 1, pp. e116-e118. DOI:
'Clinical trial design for older people - time for a rethink' QJM : an International Journal of Medicine, vol. 107, no. 1, pp. 15-16. DOI:
'The source of BNP in rheumatoid arthritis' International journal of cardiology, vol. 174, no. 3, pp. 740. DOI:
'Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study' BMJ, vol. 347, f6954. DOI:
'High-Dose Allopurinol reduces left ventricular mass in patients with ischemic heart disease' Journal of the American College of Cardiology, vol. 61, no. 9, pp. 926-32. DOI:
'Left Ventricular Hypertrophy in COPD Without Hypoxemia: The Elephant in the Room?' CHEST, vol. 143, no. 1, pp. 91-97. DOI:
'Allopurinol use is associated with greater functional gains in older rehabilitation patients' Age and Ageing, vol. 42, no. 3, pp. 400-404. DOI:
'High dose allopurinol reduces left ventricular hypertrophy and improves endothelial function in patients with chronic stable angina' European Heart Journal, vol. 33, no. S1, pp. 350-350. DOI:
'Renin-angiotensin system blockers are associated with reduced mortality and heart failure hospitalization in patients paced for complete atrioventricular block' Heart Rhythm : the Official Journal of the Heart Rhythm Society, vol. 9, no. 4, pp. 505-510. DOI:
'Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal' Arthritis & Rheumatism, vol. 64, no. 2, pp. 327-338. DOI:
'High sensitivity troponin T provides useful prognostic information in non-acute chest pain' QJM : an International Journal of Medicine, vol. 105, no. 2, pp. 159-166. DOI:
'Pulmonary hypertension predicts all-cause mortality in patients with heart failure: a retrospective cohort study' European Journal of Heart Failure, vol. 14, no. 2, pp. 162-167. DOI:
'Automated data capture from echocardiography reports to enhance hart failure population research' Heart, vol. 98, no. Suppl. 1, pp. A10-A10. DOI:
'HBA1C and mortality in diabetic individuals with heart failure: an observational cohort study' Heart, vol. 98, no. Suppl. 1, pp. A9-A10. DOI:
'The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study' Journal of the American College of Cardiology, vol. 58, no. 20, pp. 2084-2091. DOI:
'Mechanistic Insights Into the Therapeutic Use of High-Dose Allopurinol in Angina Pectoris' Journal of the American College of Cardiology, vol. 58, no. 8, pp. 820-828. DOI:
'Development of a risk score to guide brain imaging in older patients admitted with falls and confusion' British Journal of Radiology, vol. 84, no. 1004, pp. 756-757. DOI:
'Angiotensin converting enzyme inhibitor use is associated with reduced mortality in patients with aortic regurgitation' Journal of the American College of Cardiology, vol. 57, no. 14 Supplement, pp. E1307-E1307. DOI:
'The prevalence and predictors of left ventricular hypertrophy in patients with rheumatoid arthritis' Scottish Medical Journal, vol. 56, no. 1, pp. 56-56. DOI:
'A novel role for b-type natriuretic peptide (bnp) as a safe and effective rule-out test in patients referred to rapid access chest pain clinics: results of a large, prospective 1-year follow-up study' Heart, vol. 96, pp. A29-A30. DOI:
'Letter by George Regarding Article, "Uric Acid-Lowering Treatment With Benzbromarone in Patients With Heart Failure: A Double-Blind Placebo-Controlled Cross-Over Preliminary Study"' Circulation: Heart Failure, vol. 3, no. 3, pp. E10-E10. DOI:
'A new use for B-type natriuretic peptide: to detect myocardial ischaemia in non-heart failure patients' British Journal of Diabetes and Vascular Disease, vol. 10, no. 2, pp. 78-82. DOI:
'Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin' Cardiovascular Therapeutics, vol. 28, no. 3, pp. 135-138. DOI:
'Thia Zolidine Diones and the influence of media adverse reporting on prescribing attitudes in pra CTice (TZD-IMPACT) Study' British Journal of Clinical Pharmacology, vol. 68, no. 2, pp. 290-290.
'Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (tzd-impact) study' Basic & Clinical Pharmacology & Toxicology, vol. 105, pp. 140-140.
'The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) Trial A Question of Dose' Journal of the American College of Cardiology, vol. 53, no. 25, pp. 2405-2405. DOI:
'The role of urate and xanthine oxidase in vascular oxidative stress: Future directions' Therapeutics and Clinical Risk Management, vol. 5, no. 1, pp. 799-803. DOI:
'Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress' Vascular Health and Risk Management, vol. 5, no. 1, pp. 265-272. DOI:
'Allopurinol improves endothelial dysfunction by ameliorating vascular oxidative stress in patients with chronic stable angina on optimum medical therapy' Hypertension, vol. 52, no. 4, pp. 753-753.
'Endogenous xanthine oxidase causes profound vascular oxidative stress and widespread endothelial dysfunction in chronic stable angina patients despite contemporary therapy' Heart, vol. 94, pp. A3-A3.
'Aldosterone antagonism for poorly controlled hypertension in type 2 diabetes: Conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles' Heart, vol. 94, pp. A51-A52.
'Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles' Diabetologia, vol. 51, no. 5, pp. 762-768. DOI:
'Allopurinol treatment reduces arterial wave reflection in stroke survivors' Cardiovascular Therapeutics, vol. 26, no. 4, pp. 247-252. DOI:
'The association between serum urate levels and arterial stiffness/endothelial function in stroke survivors' Atherosclerosis, vol. 200, no. 2, pp. 374-379. DOI:
'The role of urate and xanthine oxidase inhibitors in cardiovascular disease' Cardiovascular Therapeutics, vol. 26, no. 1, pp. 59-64. DOI:
'Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure' Expert Opinion on Pharmacotherapy, vol. 8, no. 17, pp. 3053-3059. DOI:
'Could BNP screening of acute chest pain cases lead to safe earlier discharge of patients with non-cardiac causes? A pilot study' QJM : an International Journal of Medicine, vol. 100, no. 12, pp. 755-761. DOI:
'High dose allopurinol dramatically improves endothelial function and abolishes the vitamin-C sensitive component of oxidative stress in chronic heart failure' Scottish Medical Journal, vol. 52, no. 4, pp. 47 . DOI:
The natriuretic peptides. in GYH Lip & JE Hall (eds), Comprehensive hypertension. Mosby Elsevier, Philadelphia, pp. 349-362.
'High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid' Circulation, vol. 114, no. 23, pp. 2508-2516. DOI:
'The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients' Clinical Oncology, vol. 16, no. 1, pp. 40-47. DOI:
'Prostate cancer and antioxidants' Journal of Clinical Pharmacy and Therapeutics, vol. 26, no. 4, pp. 231-3. DOI: